Insmed Incorporated (NASDAQ:INSM) shares more than doubled after the company released positive results from its late-stage study of its experimental therapy brensocatib for a lung condition. The co...

Shares of Insmed Inc. skyrocketed Tuesday, after the biopharmaceutical company said it plans to file a New Drug Application for its treatment of non-cystic fibrosis bronchiectasis following positiv...

—Phase 3 Study Achieves Primary Endpoint for Both Dosage Strengths of Brensocatib with Statistically Significant and Clinically Meaningful Reduction in Frequency of Pulmonary Exacerbations Versus P...

—Conference Call to Take Place Tomorrow, Tuesday, May 28, 2024, at 8:00 am ET— BRIDGEWATER, N.J. , May 27, 2024 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical compan...

Insmed (INSM) Q1 earnings beat estimates while sales miss the mark. Management posts positive data readouts from mid-stage studies on its experimental inhalation powder in PH-ILD and PAH indications.

The headline numbers for Insmed (INSM) give insight into how the company performed in the quarter ended March 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estima...

Insmed (INSM) came out with a quarterly loss of $1.06 per share versus the Zacks Consensus Estimate of a loss of $1.22. This compares to loss of $1.17 per share a year ago.

Insmed (INSM) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Insmed (INSM) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Insmed (INSM) came out with a quarterly loss of $1.10 per share versus the Zacks Consensus Estimate of a loss of $1.06. This compares to loss of $1.09 per share a year ago.

Insmed is looking to broaden the use of its only approved therapy, Arikayce. The company had a record $72 million in revenue in the second quarter.

Insmed's (INSM) shares rise on positive data from the late-stage ARISE study evaluating Arikayce for newly infected lung disease caused by MAC.

Insmed Incorporated (NASDAQ:INSM) shares jumped 18% to $26.62 after the biopharmaceutical company revealed that nearly 44% of patients with nontuberculous mycobacterial (NTM) lung infection in its ...

Insmed reported positive top-line results from a late-stage study of its antibiotic drug Arikayce. The data could improve the likelihood of success in another late-stage study of Arikayce.